This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Alexion Pharmaceuticals, Inc.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Innovations by Jing Jing Wang in Myasthenia Gravis Treatment
Introduction
Jing Jing Wang is an accomplished inventor based in Woodbridge, CT (US). He has made significant contributions to the field of medical treatments, particularly in addressing refractory generalized myasthenia gravis (MG). His innovative approach has the potential to improve the quality of life for many patients suffering from this condition.
Latest Patents
Jing Jing Wang holds a patent for "Methods for treatment of refractory generalized myasthenia gravis." This patent outlines methods of treating MG in a subject in need by administering a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that binds C5 is a binding protein, such as an anti-C5 antibody. This innovative treatment method represents a significant advancement in the management of myasthenia gravis.
Career Highlights
Jing Jing Wang is currently employed at Alexion Pharmaceuticals, Inc., where he continues to work on groundbreaking research and development in the field of immunology. His expertise and dedication to improving patient outcomes have made him a valuable asset to the company.
Collaborations
Jing Jing Wang collaborates with talented professionals in his field, including Fanny O'Brien and Camille Bedrosian. These collaborations enhance the research efforts and contribute to the development of effective treatments for complex medical conditions.
Conclusion
Jing Jing Wang's innovative work in the treatment of myasthenia gravis showcases his commitment to advancing medical science. His contributions have the potential to make a lasting impact on patient care and treatment options.